Sofinnova, Polaris lead CHF 54m series-A for Noema
Sofinnova Partners and Polaris Partners have co-led a CHF 54m series-A round for Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders.
More on Early-stage
Sidekick spinoffs: Insurtech scale-ups attract PE interest
Investment set to break EUR 1.1bn mark this year as sponsors seek for rising stars
World Fund leads EUR 128m raise for quantum computing group IQM
Series-A2 for Finnish startup focused on combating the climate crisis also backed by the EIB
Gorillas raises circa USD 1bn in Delivery Hero-led Series C
New funding comes just seven months after a Series B, with the company doubling in value
French mega-rounds shoot up in 2021
France has already seen as many rounds of EUR 100m and above than in 2019 and 2020 combined, Unquote Data shows
Latest News
Adams Street secures USD 3.2bn for newest secondaries programme amid LP stakes dealflow uptick
Private markets investor has seen LP stakes increase as a proportion of its deployment over the past year, partner Jeff Akers said
Purple Ventures plans EUR 30m-EUR 40m fund to invest across CEE
Early-stage investor expects to hold a EUR 20m-plus first close for its second fund by Q1 2024
Bewater Funds nears EUR 7m close for second fund, aims to back 20 companies in next four years
Bewater II FCRE takes minority stakes (5%-25%) with tickets of EUR 500,000-EUR 2m, and it has already made three investments.
Unquote Private Equity Podcast: In conversation with... Fabio Ranghino, Ambienta
In an interview with Unquote, Ranghino discusses topics including ESG and the next phase of Ambienta’s growth